Document:

Exhibit 10.2

 

Execution Version

 

EXCHANGE AGREEMENT

 

This Exchange Agreement
(this “Agreement”) is dated September 22, 2020 (the “Effective Date”), by and among each
of the undersigned entities (the “Undersigned Entities” and each an “Undersigned Entity”),
for itself and on behalf of the beneficial owners listed on Exhibit A hereto (“Accounts”), if any,
for whom such Undersigned Entity holds contractual and investment authority (each Account, as well as such Undersigned Entity exchanging
Old Notes (as defined below) hereunder, a “Holder”), and Teligent, Inc., a Delaware corporation (the “Company”).

 

WHEREAS, the Company
is proposing to exchange (the “Exchange”) the Company’s 7.0% Cash / 8.0% PIK Series B Senior Unsecured
Convertible Notes due 2023 (CUSIP 87960W AB0) held by the Holders listed on Exhibit A hereto (the “Old Notes”)
for a new issuance of the Company’s Zero Coupon Convertible Senior Notes due 2023 (CUSIP 87960W AJ3) (the “New Notes”),
to be issued pursuant to the provisions of that certain Indenture, dated as of the date of this Agreement (the “Indenture”),
by and between the Company and Wilmington Savings Fund Society, FSB, as trustee (together with its successors and assigns, in such
capacity, the “Trustee”), upon the terms and conditions set forth herein and the other Exchange Documents (defined
below).

 

WHEREAS
each of the Undersigned Entities understands that the Exchange is being made without registration under the Securities Act of 1933,
as amended (the “Securities Act”), or any securities laws of any state of the United States or of any other
jurisdiction, and that the Exchange is only being offered to “qualified institutional buyers” (as defined in Rule 144A
under the Securities Act) in reliance upon a private placement exemption from registration under the Securities Act. The New Notes
will be issued pursuant to the Indenture (as defined herein).

 

NOW THEREFORE, on,
and subject to, the terms and conditions set forth in this Agreement, the parties hereto agree as follows:

 

Article I: Terms of the Exchange

 

Pursuant to the terms
hereof, each of the Undersigned Entities hereby agrees to cause the Holders to exchange and deliver an aggregate principal amount
of Old Notes, and in exchange therefor, the Company shall issue to the Holders an aggregate principal amount of New Notes, in each
case, as set forth on Exhibit A hereto.

 

The closing for
the Exchange (the “Closing”) shall occur on a date (the “Closing Date”) no later than
two Trading Days after the date of this Agreement. At the Closing, (a) each of the Undersigned Entities shall cause each of
its Holders to deliver to the Company all right, title and interest in and to such Holder’s Old Notes, as set forth on Exhibit
A hereto (and no other consideration), free and clear of any mortgage, lien (statutory or otherwise), pledge, charge,
security interest, encumbrance, title retention agreement or other title retention device, conditional sale or security
arrangement, collateral assignment, option, right of first refusal, equity or other adverse claim thereto or other similar
encumbrance thereon (collectively, “Liens”), together with any documents of conveyance or transfer that
the Company may reasonably deem necessary or desirable to assign, transfer to and confirm in the Company all right, title and
interest in and to such Old Notes free and clear of any Liens, and (b) the Company shall deliver or cause to be delivered to
each Holder, subject to the terms and conditions of this Agreement, New Notes having an
aggregate principal amount, as set forth on Exhibit A, which shall be equal to six hundred ninety Dollars ($690.00)
for each one thousand Dollars ($1,000.00) of the aggregate principal amount of the Old Notes plus any accrued and unpaid
interest on the Old Notes as of the Closing Date, and the Company hereby agrees to issue such New Notes to such
Undersigned Entity in exchange for such Old Notes.

 

     

     

    

 

For the avoidance of
doubt, in the event of any delay in the Closing pursuant to the immediately preceding paragraph, the Holders shall not be required
to deliver the Old Notes until the Closing occurs. Substantially concurrently with the Closing, the Company may, subject to compliance
with Section 3.37 hereof, issue the New Notes pursuant to other exchange agreements dated on or about the date hereof (“Other
Exchange Agreements”) with other holders of the Old Notes or the Company’s 4.75% Convertible Senior Notes due 2023
(CUSIP 87960W AA2) (the “Other Holders”). The delivery of the New Notes and the issuance thereof shall be effected
by book-entry delivery of an interest in a global security pursuant to DWAC to each Holder in accordance with the instructions
specified on Exhibit A hereto. The Company and the Holder shall provide such respective instructions to its respective Undersigned
Entity necessary for settlement of the Exchange. In the event the Closing does not occur, any Old Notes submitted for DWAC withdrawal
will be returned to the DTC participant that submitted the withdrawal instruction for such Old Notes in accordance with the procedures
of the Depository Trust Company (“DTC”). Each Undersigned Entity acknowledges
that all New Notes will be issued in minimum denominations of $1,000 principal amount and integral multiples of $1,000 thereafter
in accordance with the Indenture.

 

For purposes hereof:

 

“Business
Day” means any day other than a day on which federal or state banking institutions in the Borough of Manhattan, the City
of New York are authorized or obligated by law, executive order or regulation to close.

 

“Exchange
Documents” means this Agreement, the Indenture and the New Notes.

 

“Trading Day”
means any day during which trading on the Nasdaq Stock Market generally occurs.

 

Article II: Covenants, Representations
and Warranties of the Undersigned Entities and the Holders

 

Each Undersigned Entity,
for itself and on behalf of each of its Holders, hereby covenants as follows, and makes the following covenants, representations
and warranties, for itself and on behalf of each of its Holders, each of which is true and correct in all respects as of the date
hereof and shall be true and correct in all material respects (except to the extent any such covenant, representation or warranty
is qualified by materiality or reference to Material Adverse Effect, in which case, such representation or warranty shall be true
and correct in all respects) at the Closing, to the Company, and all such covenants, representations and warranties shall survive
the Closing indefinitely.

 

Section 2.1    Power
and Authorization. The Undersigned Entity and each of its Holders is duly organized, validly existing and in good
standing under the laws of the jurisdiction of its formation. The Undersigned Entity has the power, authority and capacity to execute
and deliver this Agreement for itself and on behalf of the Holders, to perform its obligations hereunder, and to consummate the
Exchange contemplated hereby. If the Undersigned Entity is executing this Agreement on behalf of Accounts, (a) the Undersigned
Entity has all requisite discretionary and contractual authority to enter into this Agreement on behalf of, and bind, each Account,
and (b) Exhibit A hereto is a true, correct and complete list of (i) the name of each Account, (ii) the
principal amount of such Account’s Old Notes, and (iii) the principal amount of New Notes to be issued to such Account in
respect of such Account’s Old Notes.

 

    2

     

    

 

Section 2.2    Valid
and Enforceable Agreement; No Violations. This Agreement has been duly executed and delivered by the Undersigned Entity
and constitutes a legal, valid and binding obligation of each of the Undersigned Entity and each of its Holders, enforceable against
each of the Undersigned Entity and each of its Holders in accordance with its terms, except that such enforcement may be subject
to (a) bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other similar laws affecting or relating
to enforcement of creditors’ rights generally, and (b) general principles of equity, whether such enforceability is
considered in a proceeding at law or in equity (the “Enforceability Exceptions”). This Agreement and consummation
of the Exchange will not violate, conflict with or result in a breach of or default under (i) the Undersigned Entity’s
or any of its other Holders’ organizational documents, (ii) any agreement or instrument to which the Undersigned Entity
or any of its other Holders is a party or by which the Undersigned Entity or any of its other Holders or any of their respective
assets are bound, or (iii) any laws, regulations or governmental or judicial decrees, injunctions or orders applicable to
the Undersigned Entity or any other Holders, except for such violations, conflicts or breaches under clauses (ii) and (iii) above
that would not, individually or in the aggregate, have a material adverse effect upon the Undersigned Entity and each of its Holders
taken as a whole.

 

Section 2.3    Title
to the Old Notes. Each Holder is the sole beneficial owner of the Old Notes set forth opposite its name on Exhibit A hereto
(or, if there are no Accounts, the Undersigned Entity is the sole legal and beneficial owner of all of the Old Notes) and, at the
Closing, will be the sole beneficial owner of the Old Notes set forth opposite its name on Exhibit A hereto (or, if there
are no Accounts, the Undersigned Entity will be the sole legal and beneficial owner of the Old Notes). The Holder has good, valid
and marketable title to its Old Notes, free and clear of any Liens (other than pledges or security interests that the Holder may
have created in favor of a prime broker under and in accordance with its prime brokerage agreement with such broker, which will
be terminated in connection with Closing). The Holder has not, in whole or in part, except as described in the immediately preceding
sentence, (a) assigned, transferred, hypothecated, pledged, exchanged or otherwise disposed of any of its Old Notes or any
of its rights, title to or interest in its Old Notes (other than to the Company pursuant hereto), or (b) given any person
or entity any transfer order, power of attorney or other authority of any nature whatsoever with respect to its Old Notes. Upon
the Holder’s delivery of its Old Notes to the Company pursuant to the Exchange, such Old Notes shall be free and clear of
all Liens.

 

Section 2.4    Qualified
Institutional Buyer. The Holder is a “qualified institutional buyer” within the meaning of Rule 144A promulgated
under the Securities Act.

 

Section 2.5    No
Affiliate Status. The Holder is not, and has not been during the consecutive three month period preceding the date
hereof, a director, officer or “affiliate” within the meaning of Rule 144 promulgated under the Securities Act (an
 “Affiliate”) of the Company. To its knowledge, the Holder did not acquire any of the Old Notes, directly or
indirectly, from an Affiliate of the Company. The Holder represents and warrants that, for purposes of Rule 144 of the Securities
Act, the Holder has continuously held the Old Notes since October 31, 2019.

 

Section
2.6    No Illegal Transactions. Each Undersigned Entity and each of its Holders has not,
directly or indirectly, and no person or entity acting on behalf of or pursuant to any understanding with either the
Undersigned Entity or such Holder has, disclosed to a third party (other than to its legal and other representatives) any
information regarding the Exchange or engaged in any transactions in the securities of the Company (including, without
limitation, any Short Sales (as defined below) involving any of the Company’s securities) since the time that the
Undersigned Entity entered into a confidentiality agreement with the Company regarding the Exchange, the issuance of the New
Notes, this Agreement, any other transactions contemplated hereby or an investment in the Common Stock or other equity
securities of the Company, which agreement is dated August 28, 2020 (the “Confidentiality Agreement”).
Each Undersigned Entity and each Holder covenants that neither it nor any person or entity acting on its behalf or pursuant
to any understanding, agreement or other arrangement with it will disclose to a third party (other than its legal and other
representatives) any information regarding the Exchange, the issuance of the New Notes, this Agreement, any other
transactions contemplated hereby or engage, directly or indirectly, in any transactions in the securities of the Company
(including Short Sales) prior to the Disclosure Time (as defined below). “Short Sales” means all
 “short sales” as defined in Rule 200 of Regulation SHO promulgated under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). Solely for purposes of this Section 2.6, subject to the Undersigned
Entity’s and each Holder’s compliance with their respective obligations under the U.S. federal securities laws
and the Undersigned Entity’s and the Holder’s respective internal policies, (a) “Undersigned Entity”
and “Holder” shall not be deemed to include any employees, subsidiaries, desks, groups or Affiliates of the
Undersigned Entity or the applicable Holder that are effectively walled off by appropriate “Fire Wall”
information barriers approved by the Undersigned Entity’s or such Holder’s respective legal or compliance
department (and thus such walled off parties have not been privy to any information concerning the Exchange), and (b) the
foregoing representations, warranties and covenants of this Section 2.6 shall not apply to any transaction by or on behalf of
an Account that was effected without the advice or participation of, or such Account’s receipt of information regarding
the Exchange provided by, the Undersigned Entity or the applicable Holder.

 

    3

     

    

 

Section 2.7    Adequate
Information; No Reliance. The Holder acknowledges and agrees that (a) the Holder has been furnished with all materials
it considers relevant to making an investment decision to enter into the Exchange and to consummate the other transactions contemplated
hereby and has had the opportunity to review the Company’s filings and submissions with the Securities and Exchange Commission
(the “SEC”), including, without limitation, all information filed or furnished pursuant to the Exchange Act,
(b) the Holder has had a full opportunity to ask questions of and receive answers from the officers of the Company concerning
the Company, their business, operations, financial performance, financial condition and prospects, and the terms and conditions
of the Exchange, (c) the Holder, together with its professional advisers, is a sophisticated and experienced investor and is capable
of evaluating, to its satisfaction, the accounting, tax, financial, legal and other risks associated with the Exchange, and that
such Holder has had the opportunity to consult with its accounting, tax, financial and legal advisors to be able to evaluate the
risks involved in the Exchange and to make an informed investment decision with respect to such Exchange, and that such Holder
is capable of sustaining any loss resulting therefrom without material injury, (d) no statement or written material contrary to
this Agreement has been made or given to the Holder by or on behalf of the Company, any of its officers, directors or employees,
or any of their respective affiliates or representatives, (e) the terms of the Exchange are the result of bilateral negotiations
among the parties and (f) the Holder is able to fend for itself in the Exchange, has such knowledge and experience in financial
and business matters as to be capable of evaluating the merits and risks of the prospective Exchange of the Old Notes and the investment
in the New Notes and has the ability to bear the economic risks of its investment and can afford the complete loss of such investment.

 

The Holder
specifically understands and acknowledges that, on the date of this Agreement and on the Closing Date, the Company may have
in its possession non-public information that could be material to the market price of the Old Notes, the New Notes and the
Company’s Common Stock into which such Old Notes and New Notes are convertible. The Holder hereby represents and
warrants that, in entering into this Agreement and consummating the transactions contemplated hereby (including, without
limitation, the Exchange), it does not require the disclosure of such non-public information to it by the Company in order to
consummate the Exchange and make an investment in the New Notes (other than disclosure of all
material terms of the Exchange (to the extent not previously publicly disclosed), which shall be disclosed by the Company
prior to the Disclosure Time), and hereby waives any and all present or future claims against the Company, any of its
officers, directors or employees, or any of their respective affiliates or representatives arising out of or relating to the
Company’s failure to disclose any such non-public information to the Holder (other than with respect to the disclosure
of all material terms of the Exchange (to the extent not previously publicly disclosed), which shall be disclosed by the
Company prior to the Disclosure Time).

 

    4

     

    

 

Section 2.8    Tax
Consequences of the Exchange. The Holder understands that the tax consequences of the Exchange will depend in part
on its own tax circumstances. The Holder acknowledges that it must consult its own tax adviser about the federal, foreign, state
and local tax consequences peculiar to its circumstances.

 

Section 2.9    Tax
Reporting. On or prior to the Closing Date, the Undersigned Entity shall deliver to the Company completed IRS Forms
W-9 or W-8, as applicable, with regards to each Holder. The Company and its agents shall be entitled to deduct and withhold from
any consideration payable pursuant to this Agreement such amounts as may be required to be deducted or withheld under applicable
law unless such Form W-9 or W-8 provided pursuant to the immediately preceding sentence establishes that such Holder is entitled
to an exemption from (or reduction in the rate of) withholding. To the extent any such amounts are withheld and remitted to the
appropriate taxing authority, such amounts shall be treated for all purposes as having been paid to the Holder to whom such amounts
would have been paid.

 

Article III: Covenants, Representations
and Warranties of the Company

 

The Company hereby
covenants as follows, and makes the following covenants, representations and warranties, each of which is true and correct in all
respects as of the date hereof and shall be true and correct in all material respects (except to the extent any such covenant,
representation or warranty is qualified by materiality or reference to Material Adverse Effect, in which case, such representation
or warranty shall be true and correct in all respects) at the Closing, to each Undersigned Entity and the Holders, and all such
covenants, representations and warranties shall survive the Closing indefinitely.

 

Section 3.1    Power
and Authorization. The Company has been duly incorporated and is validly existing as a corporation in good standing
under the laws of the jurisdiction of its incorporation and has the requisite corporate power, authority and capacity to execute
and deliver this Agreement and the applicable Exchange Documents, to perform its obligations hereunder and thereunder, and to consummate
the Exchange contemplated hereby. No material consent, approval, order or authorization of, or material registration, declaration
or filing with any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company or any of
its Subsidiaries (each, a “Governmental Entity”) is required on the part of the Company in connection with the
execution, delivery and performance by it of this Agreement and the applicable Exchange Documents, and the consummation by the
Company of the Exchange, except as may be required under any state or federal securities laws or the rules of any national securities
exchange on which the Company’s shares of common stock are traded.

 

Section
3.2    Valid and Enforceable Agreement; No Violations. This Agreement has been
duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable
against it in accordance with its terms, except that such enforcement may be subject to the Enforceability Exceptions. The
execution of this Agreement and each other Exchange Document, and consummation of the Exchange, will not violate, conflict
with or result in a breach of or default under (a) the charter, bylaws or other organizational documents of the Company,
(b) any agreement or instrument to which the Company is a party or by which the Company (or any of its assets) are
bound, or (c) any laws, regulations or governmental or judicial decrees, injunctions or orders applicable to the
Company, except for such violations, conflicts or breaches under clauses (b) and (c) above that
would not, individually or in the aggregate, have a Material Adverse Effect (defined below). 

 

    5

     

    

 

For purposes hereof:

 

“Material
Adverse Effect” means any event, occurrence, fact, condition or change, that, individually or in the aggregate, results,
or would reasonably be likely to result, in a material adverse effect on the condition (financial or otherwise) or in the earnings,
prospects, business, properties, surplus or results of operations of the Company and its Subsidiaries (as defined herein), taken
as a whole; provided, however, that any event, occurrence, fact, condition or change arising out of or attributable
to, directly or indirectly: (i) general economic or political conditions; (ii) conditions generally affecting the pharmaceuticals
industry in the US and Canada; (iii) changes in financial or securities markets in general; (iv) acts of war (whether or not declared),
armed hostilities or terrorism, or the escalation or worsening thereof; or (v) changes in applicable laws or accounting rules,
including U.S. generally accepted accounting principles (“GAAP”), in each case, shall not be deemed, either
alone or in combination, to constitute a Material Adverse Effect; provided, further, that, notwithstanding the immediately
preceding proviso, any event, occurrence, fact, condition or change referred to in clauses (i) through (iii) and (v) immediately
above shall only be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be likely
to occur to the extent that such event, occurrence, fact, condition or change has a disproportionate effect on the Company and
its Subsidiaries, taken as a whole, compared to other entities whose primary business is in the pharmaceuticals industry in the
U.S. and Canada.

 

“Senior Credit
Facilities” means the credit facilities, as amended from time to time, under (i) that certain First Lien Revolving Credit
Agreement, dated as of December 13, 2018, by and among the Company, the subsidiaries of the Company from time to time party thereto
as guarantors, the lenders from time to time party thereto and ACF FINCO I LP, as administrative agent and collateral agent, and
(ii) that certain Second Lien Credit Agreement, dated as of December 13, 2018, by and among the Company, the subsidiaries of the
Company from time to time party thereto as guarantors, the lenders from time to time party thereto and Ares Capital Corporation,
as administrative agent and collateral agent.

 

Section 3.3    Authorization
of the New Notes. The New Notes to be issued by the Company to the Holders under this Agreement will be in the form contemplated
by the Indenture, have been duly authorized by the Company for issuance pursuant to this Agreement and the Indenture, when issued
will have been duly executed by the Company in accordance with the terms of the Indenture and, when authenticated in the manner
provided for in the Indenture and delivered and paid for in accordance with the terms of the Exchange, will be validly issued and
delivered and will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with
their terms, except as such enforceability may be limited by the Enforceability Exceptions. Upon the Company’s delivery of
the New Notes to the Holder (or any Undersigned Entity) pursuant to the Exchange, such New Notes will be entitled to the benefits
of the Indenture and shall be free and clear of all Liens created by the Company.

 

Section
3.4    Indenture. The Indenture has been duly and validly authorized by the Company
and, on the Closing Date, will be duly executed and delivered by the Company, and assuming due authorization, execution and
delivery by the Trustee, will constitute the valid and binding agreement of the Company, enforceable against the Company in
accordance with its terms, except as such enforceability may be limited by the Enforceability Exceptions.

 

    6

     

    

 

Section
3.5    Exemption from Registration. Assuming the accuracy of the representations and warranties
of the Holders and each other Holder executing an Exchange Agreement, (a) the issuance of the New Notes in connection with the
Exchange pursuant to this Exchange Agreement is exempt from the registration requirements of the Securities Act; (b) the
New Notes issued to the Holder and/or the Undersigned Entity (1) will be issued in compliance with all applicable state and
federal laws concerning the issuance of the New Notes and (2) will be issued to the Holders through the facilities of DTC;
and (c) the Indenture is not required to be qualified under the Trust Indenture Act of 1939, as amended. The New Notes, when issued,
will not be of the same class as securities listed on a national securities exchange registered under Section 6 of the Exchange
Act, or quoted in a U.S. automated inter-dealer quotation system, within the meaning of Rule 144A(d)(3)(i) under the Securities
Act. For the purposes of Rule 144 promulgated under the Securities Act, the Company acknowledges that, assuming the accuracy of
each Holder’s representations and warranties hereunder, the holding period of the Holder’s New Notes may be tacked
onto the holding period of the Old Notes and the Company agrees not to take a position contrary thereto. 

 

Section 3.6 Validity
of Underlying Common Stock. The New Notes will, at the Closing, be convertible into shares of Common Stock, par value $0.01
per share of the Company (the “Conversion Shares”) in accordance with the terms of the Indenture. Upon execution
and delivery of the Indenture by the Company, the Conversion Shares will be duly authorized and reserved by the Company for issuance
upon conversion of the New Notes and, when issued upon conversion of the New Notes in accordance with the terms of the New Notes
and the Indenture, will be validly issued, fully paid and non-assessable, and the issuance of the Conversion Shares will not be
subject to any preemptive, participation, rights of first refusal or other similar rights in effect as of the Closing Date. For
the purposes of Rule 144 promulgated under the Securities Act, the Company acknowledges that, assuming the accuracy of each Holder’s
representations and warranties hereunder, the holding period of the Conversion Shares may be tacked onto the holding period of
the Old Notes and the New Notes and the Company agrees not to take a position contrary thereto.

 

Section 3.7    Listing
Approval. At the Closing, the Conversion Shares shall be approved for listing on the Nasdaq Stock Market, subject to the
notice of issuance.

 

Section
3.8    Disclosure. Prior to 9:00 a.m. prevailing Eastern time on the day after the date
hereof (the “Disclosure Time”), the Company shall issue a publicly available press release or file with
the SEC a Current Report on Form 8-K disclosing all material terms of the Exchange (to the extent not previously
publicly disclosed). The Company hereby agrees and acknowledges that (a) the Company has not provided to the Undersigned
Entity or any Holder (or any of their respective affiliates) any material non-public information with respect to the Company
other than (i) the material terms of the Exchange and (ii) certain other information that is no longer material
non-public information by reason of cleansing disclosure made prior to the date hereof (or that has become immaterial and
stale by reason of the passage of time), (b) between the signing of this Exchange Agreement and the Closing, the Company
shall not provide any material non-public information to the Undersigned Entity or any Holder (or any of their respective
affiliates), and (c) the Company agrees that any non-use and/or non-trading obligations of the Undersigned Entity or any
other Holder (or any of their respective affiliates) to the Company, whether written or oral (including under the
Confidentiality Agreement), is hereby terminated as of the Disclosure Time (whether or not the Company makes the public
disclosure required by the first sentence of this Section 3.8). Without the prior written consent of the Undersigned Entity,
the Company shall not disclose the name of the Undersigned Entity or any Holder in any filing or announcement, unless such
disclosure is required by applicable law, rule, regulation or legal process based on advice of counsel.

 

    7

     

    

 

Section 3.9    Investment
Company Act.  The Company is not and, after giving effect to the transactions contemplated by this Agreement, will
not be required to register as an “investment company” or an entity “controlled” by an “investment
company” within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder.

 

Section 3.10    Organization
and Qualification of the Company’s Subsidiaries. Each of the Company’s subsidiaries (which, for purposes of
this Agreement, shall mean (a) any corporation more than 50% of whose voting stock having by the terms thereof power to elect a
majority of the directors of such corporations at the time owned by the Company directly or indirectly and (b) any partnership,
association, joint venture or other entity in which the Company directly or indirectly has more than 50% voting equity interest
at the time, in each case of clauses (a) and (b) that provides or is required to provide a guarantee of the Company’s obligations
in respect of the New Notes (each, a “Subsidiary” and collectively, the “Subsidiaries”))
is a direct or indirect wholly owned subsidiary of the Company. Each Subsidiary has been duly incorporated or organized, as the
case may be, is validly existing as a corporation or limited liability company, as applicable, in good standing under the laws
of the jurisdiction of its incorporation or organization, has the power and authority (corporate or other) to own its property
and to conduct its business and is duly qualified to transact business and is in good standing in each jurisdiction in which the
conduct of its business requires such qualification, except to the extent that the failure to be so qualified or be in good standing
would not have a Material Adverse Effect. All of the issued and outstanding shares of capital stock or other equity interests of
each Subsidiary have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly
by the Company, free and clear of all Liens (other than Liens granted to secure the Senior Credit Facilities).

 

Section 3.11    Common
Stock. All of the outstanding shares of Common Stock have been duly authorized and validly issued, are fully paid and non-assessable
and were issued in compliance with applicable securities laws. None of the outstanding shares of Common Stock is entitled or subject
to any preemptive right, right of participation, right of maintenance, right of repurchase or forfeiture, subscription right or
any similar right and none of the outstanding shares of Common Stock is subject to any right of first refusal. The description
of the Common Stock conforms in all material respects to all statements relating thereto contained in the Company’s reports
filed under the Exchange Act with the SEC (collectively, “SEC Reports”).

 

Section 3.12    Absence
of Existing Defaults and Conflicts. None of the Company or its Subsidiaries (a) is in violation of its charter or bylaws
(or any equivalent documents) or (b) after giving effect to the Exchange and the transactions contemplated thereby, will be in
default (or with the giving of notice or lapse of time would be in default) under any existing obligation, agreement, covenant
or condition contained in any indenture, loan agreement, mortgage, lease or other agreement or instrument to which any of them
is a party or by which any of them is bound or to which any of the properties of any of them is subject, except such defaults that
would not, individually or in the aggregate, have a Material Adverse Effect.

 

Section
3.13    No Material Adverse Effect in Business. Except as disclosed in the SEC Reports, and
other than effects on the business related primarily to COVID-19, since March 31, 2020 through the date hereof, (a) there has
been no Material Adverse Effect, nor any development or event which would result in a Material Adverse Effect, (b) there has
been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock and (c)
there has been no material adverse change in the capital stock, short-term indebtedness, long-term indebtedness, net current
assets or net assets of the Company and its Subsidiaries.

 

    8

     

    

 

Section 3.14    Legal
Proceedings. Except as described in the SEC Reports, there is no legal or governmental action, investigation or proceeding
pending or, to the Company’s knowledge, threatened against the Company or its Subsidiaries (a) asserting the invalidity of
any of the Exchange Documents; (b) seeking to prevent the issuance of the New Notes or the consummation of any of the transactions
provided for in the Exchange Documents; or (c) that would materially and adversely affect the ability of the Company to perform
its obligations under, or the validity or enforceability of, any of the Exchange Documents.

 

Section 3.15    Possession
of Permits. The Company and its Subsidiaries have all requisite power and authority, and all authorizations, approvals,
orders, licenses in the various states in which they do business, certificates and permits of and from regulatory or governmental
officials, bodies and tribunals that are necessary to own or lease their respective properties (collectively, “Permits”),
in each case, that are material to the Company taken as a whole. The Company and its Subsidiaries, as applicable, are in compliance
with the terms and conditions of all such Permits, except where the failure so to comply would not, singly or in the aggregate,
result in a Material Adverse Effect. All of the Permits are valid and in full force and effect, except where the invalidity of
such Permits or the failure of such Permits to be in full force and effect would not result in a Material Adverse Effect, and the
Company has not received any notice of proceedings by a Governmental Entity relating to the revocation or modification of any such
Permits which, singly or in the aggregate, may reasonably be expected to result in a Material Adverse Effect.

 

Section 3.16    Title
to Property. The Company and its Subsidiaries have good and marketable title to all real property owned by them and good
title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests,
claims or defects, restrictions or encumbrances of any kind except such as (A) are described in the SEC Reports or (B) would not,
singly or in the aggregate, result in a Material Adverse Effect; and all of the leases and subleases of real property of the Company
and its Subsidiaries, considered as one enterprise, and under which the Company or any of its Subsidiaries holds properties described
in the SEC Reports, are in full force and effect, with such exceptions as do not materially
interfere with the use made or proposed as of the date hereof to be made of such property by the Company and its subsidiaries.

 

Section
3.17    Intellectual Property. The Company and its Subsidiaries own, license or otherwise have
rights in all United States and foreign patents, trademarks, service marks, tradenames, copyrights, trade secrets and other
proprietary rights necessary for the conduct of their business as currently carried on and as proposed to be carried on, in
each case, as described in the SEC Reports (collectively and together with any applications or registrations for the
foregoing, the “Intellectual Property”). Except as specifically described in the SEC Reports, (a) no
third parties have obtained rights to any such Intellectual Property from the Company, other than licenses granted in the
ordinary course and rights that would not have a Material Adverse Effect; (b) to the Company’s knowledge, there is
no infringement or misappropriation by third parties of any such Intellectual Property; (c) there is no pending or, to
the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s rights
in or to any such Intellectual Property, and the Company is unaware of any facts that would form a reasonable basis for any
such claim; (d) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim
by others challenging the validity, enforceability or scope of any such Intellectual Property, and the Company is unaware of
any facts that would form a reasonable basis for any such claim; (e) there is no pending or, to the Company’s
knowledge, threatened action, suit, proceeding or claim by others that the Company has, or any of its products, product
candidates or services described in the SEC Reports that infringes, misappropriates or otherwise violates, or would infringe
upon, misappropriate or otherwise violate, upon the commercialization of such products, product candidates or services
described in the SEC Reports, any patent, trademark, copyright, trade secret or other proprietary right of others, and the
Company is unaware of any facts that would form a reasonable basis for any such claim; (f) to the Company’s
knowledge, there is no patent or patent application that contains claims that cover or may cover any Intellectual Property
described in the SEC Reports as being owned by or licensed to the Company, or that is necessary for the conduct of its
business as currently conducted or contemplated, or that interferes with the issued or pending claims of any such
Intellectual Property; (g) to the Company’s knowledge, there is no prior art or public or commercial activity of
which the Company is aware that may form a reasonable basis to render any patent held by the Company invalid or any patent
application held by the Company unpatentable that has not been disclosed to the U.S. Patent and Trademark Office; and
(h) the Company has not committed any act or omitted to undertake any act for which the effect of such commission or
omission would reasonably be expected to render the Intellectual Property invalid or unenforceable, in whole or in part,
except to the extent such invalidity or unenforceability would not reasonably be expected to have a Material Adverse Effect.
To the Company’s knowledge, none of the technology employed by the Company has been obtained or is being used by the
Company in violation of the rights of any person or third party. There are no outstanding options, licenses or agreements of
a material nature relating to the Intellectual Property owned by the Company that are required to be described in the SEC
Reports and are not described therein as so required.

 

    9

     

    

 

Section 3.18    Absence
of Labor Dispute. No labor disputes with the employees of the Company or any of its Subsidiaries exist or, to the knowledge
of the Company, are imminent that would, individually or in the aggregate, result in a Material Adverse Effect.

 

Section
3.19    Accounting Controls and Disclosure Controls. The Company maintains internal control
over financial reporting (as defined under Rule 13a-15 and 15d-15 under the Exchange Act and the rules and regulations of the
Commission promulgated thereunder) in compliance with the requirements of the Exchange Act and a system of internal
accounting controls sufficient to provide reasonable assurances that (a) transactions are executed in accordance with
management’s general or specific authorization; (b) transactions are recorded as necessary to permit preparation of
financial statements in conformity with GAAP and to maintain accountability for assets; (c) access to assets is permitted
only in accordance with management’s general or specific authorization; (d) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
and (e) the interactive data in eXtensible Business Reporting Language contained or incorporated by reference in the SEC
Reports fairly presents the information called for in all material respects and is prepared in accordance with the
Commission’s rules and guidelines applicable thereto. Except as disclosed in the SEC Reports, since June 30, 2020,
there has been (x) no material weakness in the Company’s internal control over financial reporting (whether or not
remediated) and (y) no change in the Company’s internal control over financial reporting that has materially affected,
or is reasonably likely to materially affect, the Company’s internal control over financial reporting. Except as
disclosed in the SEC Reports, the Company and each of its Subsidiaries maintain a system of disclosure controls and
procedures (as defined in Rule 13a-15 and Rule 15d-15 under the Exchange Act and the rules and regulations of the Commission
promulgated thereunder) that are designed to ensure that information required to be disclosed by the Company in the reports
that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the Commission’s rules and forms, and is accumulated and communicated to the Company’s management,
including its principal executive officer or officers and principal financial officer or officers, as appropriate, to allow
timely decisions regarding disclosure. As disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2020, as of June 30, 2020, the Company’s management, with participation of the Company’s Chief
Executive Officer and Chief Financial Officer, carried out evaluations of the design and operation of the Company’s
disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act, and based upon that evaluation, the
Company’s Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2020, the design and
operation of the Company’s disclosure controls and procedures were not effective to accomplish their objectives at the
reasonable assurance level.

 

    10

     

    

 

Section 3.20    Compliance
with the Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or any of the Company’s
directors or officers, in their capacities as such, in each case, to comply in all material respects with any applicable provision
of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including Section 402 related
to loans and Sections 302 and 906 related to certifications.

 

Section 3.21    Financial
Statements. The audited financial statements of the Company as of and for the period ended December 31, 2019 (together
with the related schedules and notes thereto, the “Audited Financial Statements”) contained in the Company’s
Form 10-K for the period ended December 31, 2019 have been prepared, and fairly present, in all material respects, the assets,
liabilities, equity, financial condition, results of operations and cash flows of the Company at the respective dates and for the
respective periods (as the case may be) indicated, in accordance with GAAP consistently applied throughout such period (except
as specified therein). The unaudited interim financial statements of the Company as of and for the period ended June
30, 2020 (“Interim Financial Statements” and, together with the Audited Financial Statements, the “Financial
Statements”) contained in the Company’s Form 10-Q for the period ended June
30, 2020 have been prepared in conformity with GAAP and present fairly in all material respects the information required
to be stated therein. Since the respective dates of the Financial Statements contained in the Company’s SEC Reports, there
has been no change which could, or any development that would, reasonably be expected to (a) have a Material Adverse Effect, (b)
adversely affect the issuance or validity of the New Notes or (c) adversely affect the consummation of any of the transactions
contemplated by any of the Exchange Documents.

 

Section 3.22    No
Undisclosed Liabilities. The Company does not have any material liabilities, whether known or unknown, asserted or unasserted,
absolute or contingent, accrued or unaccrued, liquidated or unliquidated, and due or to become due, including any liability for
taxes (and there is no past or present fact, situation, circumstance, condition or other basis for any present or future action,
suit, proceeding, hearing, charge, complaint, claim or demand against the Company giving rise to any such liability), except (a)
for liabilities set forth in the Financial Statements; and (b) normal fluctuation in the amount of the liabilities referred to
in clause (a) above occurring in the ordinary course of business of the Company since the date of the most recent balance sheet
included in the Financial Statements.

 

Section
3.23    Payment of Taxes. All U.S. federal income tax returns of the Company and its
Subsidiaries required by applicable law to be filed have been filed and all material taxes shown by such returns or otherwise
assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly
taken and as to which adequate reserves have been provided. The Company and its Subsidiaries have filed all other tax returns
that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the
failure to file such returns would not result in a Material Adverse Effect, and the Company and its Subsidiaries have paid
all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its Subsidiaries, except for
such taxes, if any, (i) as are being contested in good faith and as to which adequate reserves have been established by the
Company or (ii) where the failure to pay such taxes would not result in a Material Adverse Effect.

 

    11

     

    

 

Section 3.24    Foreign
Corrupt Practices Act. None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any director,
officer, agent, employee, or affiliate acting on behalf of the Company or any of its Subsidiaries is aware of or has taken any
action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977,
as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use
of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay
or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything
of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official
thereof or any candidate for foreign political office, in contravention of the FCPA, and the Company and, to the knowledge of the
Company, its affiliates have conducted their businesses in compliance with the FCPA. The Company and its Subsidiaries have instituted
and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
therewith.

 

Section 3.25    Anti-Money
Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related
or similar applicable rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively,
the “Money Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving
the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company,
threatened.

 

Section 3.26    OFAC.
None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate
or person acting on behalf of the Company or any of its Subsidiaries is an individual or entity currently the subject or target
of any sanctions administered or enforced by the U.S. Government, including, without limitation, the U.S. Department of the Treasury’s
Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other
relevant sanctions authority (collectively, “Sanctions”). Except as permitted by U.S. and other applicable law,
the Company is not located, organized or resident in a country or territory that is the subject of Sanctions (including, without
limitation, Burma, Cuba, Iran, North Korea, Sudan and Syria); and the Company will not directly or indirectly lend, contribute
or otherwise make available funds to any subsidiaries, joint venture partners or other individual or entity, to fund any activities
of or business with any individual or entity, or in any country or territory, that, at the time of such funding, is the subject
of Sanctions or in any other manner that will result in a violation by any individual or entity (including any individual or entity
participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.

 

Section 3.27    Cybersecurity.
Except as disclosed in the SEC Reports, (a) to the knowledge of the Company, there has been no security breach or incident, unauthorized
access or disclosure, or other compromise of or relating to the Company or its Subsidiaries information technology and computer
systems, networks, hardware, software, data and databases (including the data and information of their respective customers, employees,
suppliers, vendors and any third-party data maintained, processed or stored by the Company and its Subsidiaries, and any such
data processed or stored by third parties on behalf of the Company and its Subsidiaries), equipment or technology (collectively,
 “IT Systems and Data”) that, individually or in the aggregate, would reasonably be expected to have a Material
Adverse Effect, (b) neither the Company nor its Subsidiaries have been notified in writing of, and, to the Company’s knowledge,
there is no presently existing event or condition that would result in, any security breach or incident, unauthorized access or
disclosure or other compromise to their IT Systems and Data that, individually or in the aggregate, would reasonably be expected
to have a Material Adverse Effect and (c) the Company and its Subsidiaries have implemented appropriate controls, policies, procedures,
and technological safeguards reasonably designed to maintain and protect the integrity, continuous operation, redundancy and security
of their IT Systems and Data as required by applicable law. The Company and its Subsidiaries are presently in compliance in all
material respects with all applicable laws or statutes and all applicable judgments, orders, rules and regulations of any court
or arbitrator or governmental or regulatory authority, internal policies and applicable contractual obligations relating to the
privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except for such noncompliance as would not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect.

 

    12

     

    

 

Section 3.28    No
Finder’s Fees. Except as contemplated by this Agreement or as otherwise previously disclosed to each of the Undersigned
Entities, the Company has neither paid, nor is a party to any contract or agreement to pay, to any person or entity any compensation
for soliciting another to consummate the Exchange and there are no contracts, agreements or understandings between the Company
and any person that would give rise to a valid claim against the Company for a commission, finder’s fee or other like payment
in connection with the Exchange.

 

Section 3.29    No
Integration. Neither the Company, nor any other person acting on behalf of the Company, has, directly or indirectly, solicited
any offer to buy, sold or offered to sell any security which is or would be integrated with the Exchange pursuant to the Securities
Act, the rules and regulations thereunder or the interpretations thereof by the SEC.

 

Section 3.30    Absence
of Further Requirements. No consent, approval, authorization, or order of, or filing or registration with, any Governmental
Entity is required for the consummation of the transactions contemplated by this Agreement and the Indenture in connection with
the Exchange and the transactions contemplated thereby, other than (a) the filing of a notice of listing of additional shares and
related materials with the Nasdaq Stock Market and (b) any filings under the Exchange Act, which have been or will be made when
and how required.

 

Section 3.31    Accountants.
Deloitte & Touche LLP, who has audited the Company’s Audited Financial Statements included in the SEC Reports, are registered
independent public accountants as required by the Securities Act and the rules and regulations promulgated thereunder and by the
rules of the Public Company Accounting Oversight Board.

 

Section
3.32    Compliance with Law. Except as disclosed in the SEC Reports, none of the Company nor
its Subsidiaries have been advised in writing that the Company and its Subsidiaries are not conducting business in compliance
with all applicable laws, rules and regulations of the jurisdictions in which they are conducting business, including,
without limitation, all applicable local, state and federal laws and regulations, except, in each case, where failure to be
so in compliance, individually or in the aggregate, would not result in a Material Adverse Effect. Except as disclosed in the
SEC Reports, the Company is, and since January 1, 2018 has been, in compliance in all material respects with the Federal
Food, Drug & Cosmetics Act, and the applicable regulations administered thereunder by the Food and Drug Administration
(“FDA”), the Public Health Service Act and any other similar applicable law administered by the FDA or
other comparable Governmental Entity responsible for regulation of the development, clinical testing, manufacturing, sale,
marketing, distribution and importation or exportation of drug and biopharmaceutical products of similar nature to those
developed by the Company (each, a “Drug Regulatory Agency”), except, in each case, for any noncompliance,
either individually or in the aggregate, which would not result in a Material Adverse Effect. Except as disclosed in the SEC
Reports, no investigation, claim, suit, proceeding, audit or other action by any Governmental Entity is pending or, to the
Company’s knowledge, threatened against the Company. There is no agreement, judgment, injunction, order or decree
binding upon the Company which (a) has or would reasonably be expected to have the effect of prohibiting or materially
impairing any business practice of the Company, any acquisition of material property by the Company or the conduct of
business by the Company in any material respect as currently conducted, (b) is reasonably likely to have an adverse effect on
the Company’s ability to comply with or perform any covenant or obligation under any Exchange Document or (c) is
reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering in any material respect
with the Exchange or the issuance of the New Notes. Except as disclosed in the SEC Reports, there are no proceedings pending
or, to the Company’s knowledge, threatened with respect to an alleged material violation by the Company of the Federal
Food, Drug & Cosmetics Act and the FDA regulations adopted thereunder, the Public Health Service Act or any other similar
law administered or promulgated by any Drug Regulatory Agency. All clinical, pre-clinical and other studies and tests
conducted by or on behalf of, or sponsored by, the Company, or in which the Company or its current products or product
candidates have participated, were and, if still pending, are being, conducted in all material respects in accordance with
applicable standard medical and scientific research procedures and in compliance in all material respects with the applicable
regulations of any applicable Drug Regulatory Agency and other applicable law. The Company and its Subsidiaries hold all
required governmental authorizations issuable by any Drug Regulatory Agency necessary for the conduct of the business of the
Company as currently conducted, and development, clinical testing, manufacturing, marketing, distribution and importation or
exportation, as currently conducted, of any of its products or product candidates.

 

    13

     

    

 

Section 3.33    Related
Party Transactions. There are no relationships between or among the Company, on the one hand, and its affiliates, officers
or directors on the other hand, or between any Subsidiary, on the one hand, and its affiliates, officers or directors on the other
hand, that are required to be described under applicable securities laws in the SEC Reports, that is not so described in such filings.

 

Section 3.34    Off-Balance
Sheet Arrangements. There is no transaction, arrangement or other relationship between the Company or any Subsidiary and
an unconsolidated or other off-balance sheet entity that (a) is required to have been described under applicable securities laws
in the SEC Reports that is not so disclosed or (b) otherwise would be reasonably likely to result in a Material Adverse Effect.
There are no such transactions, arrangements or other relationships with the Company or any Subsidiary that may create material
contingencies or liabilities that have not been otherwise disclosed by the Company in the SEC Reports as required by applicable
law.

 

Section
3.35    Environmental Matters. There has been no storage, disposal, generation, manufacture,
transportation, handling or treatment of toxic wastes, hazardous wastes or hazardous substances by the Company or any
Subsidiary (or, to the knowledge of the Company, any of their predecessors in interest) at, upon or from any of the property
now or previously owned or leased by the Company or any Subsidiary, in each case, (a) in violation of any applicable law,
ordinance, rule, regulation, order, judgment, decree or permit or (b) that would require remedial action under any applicable
law, ordinance, rule, regulation, order, judgment, decree or permit, except, in each of the cases of the foregoing clauses
(a) and (b), where such violation or remedial action would not, individually or in the aggregate, have a Material Adverse
Effect. There has been no spill, discharge, leak, emission, injection, escape, dumping or release of any kind into such
property or into the environment surrounding such property of any toxic wastes, medical wastes, solid wastes, hazardous
wastes or hazardous substances due to or caused by the Company or any Subsidiary which, in each case, would reasonably be
expected to have a Material Adverse Effect.

 

    14

     

    

 

Section 3.36    Nasdaq
Listing. The shares of Common Stock are listed on the Nasdaq Stock Market. Except as described in the SEC Reports, (a)
the Company has not received any delisting notice relating to the shares of Common Stock listed on the Nasdaq Stock Market and
(b) the Company is in compliance with the applicable current listing and governance rules and requirements of the Nasdaq Stock
Market.

 

Section 3.37    Terms
and Conditions of Other Agreements. The terms of any Other Exchange Agreements with any Other Holders are not more favorable
in any material respect to such Other Holders than to the Holders under the terms of this Agreement; it being understood that any
Other Exchange Agreements with any holder of 4.75% Convertible Senior Notes due 2023 do not contain a waiver or release of claims.
The Company shall not amend the terms of any Other Exchange Agreement such that the terms of such Other Exchange Agreement are
more favorable to the Other Holder party thereto than the terms of this Agreement to the Undersigned Entity and each Holder, unless
the Company simultaneously causes this Agreement to be amended to contain substantially similar terms as such Other Exchange Agreement.

 

Article IV: Conditions to Closing.

 

Section 4.1    Conditions
to the Undersigned Entities’ and Holders’ Obligations. The obligations of each Undersigned Entity and each
Holder to consummate the transactions contemplated by this Agreement are subject to the accuracy of the representations and warranties
set forth in Article III, which shall be true and correct in all material respects (except to the extent any such representation
or warranty is qualified by materiality or reference to Material Adverse Effect, in which case, such representation or warranty
shall be true and correct in all respects) as of the Closing with the same effect as though such representations and warranties
had been made as of the Closing, and to the timely performance by the Company of its covenants and obligations hereunder, and
to the satisfaction or waiver prior to or at the Closing, of each of the following conditions:

 

		(a)	The Company shall deliver (or cause to be delivered) the New Notes to each Holder in the principal
amounts set forth on Exhibit A hereto in accordance with the delivery terms set forth in Article I.

 

		(b)	The Company shall have publicly disclosed the material terms of the transaction on or prior to
the Disclosure Time (to the extent not previously publicly disclosed).

 

		(c)	The Company shall have provided evidence that it has delivered to American Stock Transfer &
Trust Company, LLC, the transfer agent of the Company, an executed instruction letter to reserve a sufficient number of shares
of Common Stock to effectuate the maximum conversion of all New Notes issued in connection with the Exchange.

 

		(d)	The Company shall have received confirmation that the Nasdaq Stock Market has completed its review
of the Exchange and the transactions contemplated thereby and that the Conversion Shares shall be approved for listing on the Nasdaq
Stock Market, subject to the notice of issuance.

 

    15

     

    

 

		(e)	The Company shall have received all necessary consents, required to consummate the Exchange and
the transactions contemplated thereby.

 

		(f)	The Company shall have received confirmation that the CUSIP for the New Notes shall be eligible
for custody by, and settlement through the facilities of, DTC.

 

The obligation of each Undersigned Entity
and each Holder to deliver the Old Notes is further subject to the issuance and authentication by the Trustee of the New Notes
pursuant to the terms of the Indenture, represented by one or more global securities registered in the name of a nominee of DTC,
whereby the beneficial interests in the New Notes of such Holders will be represented through book-entry accounts of financial
institutions acting on behalf of such beneficial owners as direct or indirect participants in DTC.

 

Section 4.2    Conditions
to the Company’s Obligations. The obligations of the Company to consummate the transactions contemplated by this
Agreement are subject to the accuracy of the representations and warranties set forth in Article II, which shall be true
and correct in all material respects (except to the extent any such representation or warranty is qualified by materiality or
reference to Material Adverse Effect, in which case, such representation or warranty shall be true and correct in all respects)
as of the Closing with the same effect as though such representations and warranties had been made as of the Closing, and to the
timely performance by each Undersigned Entity and each Holder, as applicable, of the their covenants and obligations hereunder,
and to the satisfaction or waiver prior to or at the Closing, of each of the following conditions:

 

		(a)	The Holders shall deliver (or cause to be delivered) the Old Notes to the Company in the principal
amounts set forth on Exhibit A hereto, and in accordance with the delivery terms set forth in Article I.

 

		(b)	The Company shall have entered into Other Exchange Agreements with all Other Holders.

 

The obligation of the Company to deliver
the New Notes is further subject to the prior receipt by the Company of a valid DWAC withdrawal conforming with the aggregate principal
amount of the Old Notes to be exchanged by such Holder in connection with the Exchange.

 

Article V: Certain Covenants

 

Section 5.1    Further
Assurances. The parties hereto agree to use commercially reasonable efforts to take, or cause to be taken, all reasonable
actions, to file, or cause to be filed, all documents and to do, or cause to be done, all things necessary, proper or advisable
to consummate the Exchange on their account, including preparing and filing as promptly as practicable all documentation to effect
all necessary filings, consents, waivers, approvals, and authorizations.

 

Section 5.2   Covenant
Survival. The obligations of the Company under this Article V shall survive the payment or transfer of any New
Note, the enforcement, amendment or waiver of any provision of this Agreement or the New Notes, and the termination of this Agreement.

 

Section 5.3    Release.
In consideration of the promises of the Company contained herein, the Holder releases and discharges the Company and the Company’s
officers, directors, principals, control persons, past and present employees, insurers, successors, and assigns (collectively,
the “Company Parties”) from all actions, cause of action, suits, debts, dues, sums of money, accounts, reckonings,
bonds, bills, specialties, covenants, contracts, controversies, agreements, promises, variances, trespasses, damages, judgments,
extents, executions, claims, and demands whatsoever, in law, admiralty or equity, against the Company Parties which Holder ever
had, now has or hereafter can, shall or may, have for, upon, or by reason of any matter, cause or thing whatsoever, whether or
not known or unknown, arising under the Old Notes. It being understood that this Section 5.3 shall be limited in all respects
to only matters arising under or related to the Old Notes and shall under no circumstances constitute a release, waiver or discharge
with respect to the Exchange Documents or limit the Holder from taking action for matters with respect to the Exchange Documents
or events that may arise in the future.

 

    16

     

    

 

Article VI: Miscellaneous

 

Section 6.1    Entire
Agreement. This Agreement and any documents and agreements executed in connection with the Exchange embody the entire
agreement and understanding of the parties hereto with respect to the subject matter hereof and supersede all prior and contemporaneous
oral or written agreements, representations, warranties, contracts, correspondence, conversations, memoranda and understandings
between or among the parties or any of their agents, representatives or affiliates relative to such subject matter, including,
without limitation, any term sheets, emails or draft documents.

 

Section 6.2    Construction. For
purposes of this Agreement, the words “hereof,” “herein,” “hereby” and other words of similar
import refer to this Agreement as a whole unless otherwise indicated. Whenever the singular is used herein, the same shall include
the plural, and whenever the plural is used herein, the same shall include the singular, where appropriate. The term “including”
means “including but not limited to.” The word “or” shall not be exclusive. Whenever used in this Agreement,
the masculine gender shall include the feminine and neutral genders. All references herein to Articles, Sections, Subsections,
Paragraphs and Exhibits shall be deemed references to Articles and Sections and Subsections and Paragraphs of, and Exhibits to,
this Agreement unless the context shall otherwise require. Any reference herein to any statute, agreement or document, or any section
thereof, shall, unless otherwise expressly provided, be a reference to such statute, agreement, document or section as amended,
modified or supplemented (including any successor section) and in effect from time to time. All terms defined in this Agreement
shall have the defined meaning when used in any Exhibit, Schedule, certificate or other documents attached hereto or made or delivered
pursuant hereto unless otherwise defined therein. The parties acknowledge and agree that, except as specifically provided herein,
they may pursue judicial remedies at law or in equity in the event of a dispute with respect to the interpretation or construction
of this Agreement. This Agreement shall be interpreted and enforced in accordance with the provisions hereof without the aid of
any canon, custom or rule of law requiring or suggesting construction against the party causing the drafting of the provision in
question.

 

Section 6.3    Governing
Law. This Agreement shall in all respects be construed in accordance with and governed by the substantive laws of
the State of New York, without reference to its choice of law rules.

 

Section 6.4    Counterparts. This
Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which taken together shall constitute
one and the same instrument. Any counterpart or other signature hereon delivered by facsimile or other electronic transmission
shall be deemed for all purposes as constituting good and valid execution and delivery of this Agreement by such party.

 

Section 6.5    Notices.
All notices or other communications required or permitted under this Agreement shall be in writing and shall be deemed given or
delivered: (i) when delivered personally; (ii) one business day following deposit with a recognized overnight courier service,
provided such deposit occurs before the deadline imposed by that service for overnight delivery or (iii) when transmitted, if
sent by electronic mail, provided confirmation of receipt tis received by send and the notice is sent by an additional method
provided under this Agreement, in each case to the parties hereto as follows:

 

    17

     

    

 

If to a Holder, to the address set forth
on such Holder’s signature page to this Agreement, with a copy (which shall not constitute notice) to:

 

[   •   ]

 

If to the Company:

 

Teligent, Inc.

105 Lincoln Avenue, PO Box 687

Buena, New Jersey 08310

Attention: Timothy B. Sawyer, President
and Chief Executive Officer

Email: tsawyer@teligent.com

 

With a copy (which shall not constitute
notice) to:

 

K&L Gates LLP

599 Lexington Avenue

New York, New York 10022

Attention: Whitney J. Smith

Email:  whitney.smith@klgates.com

 

and

 

K&L Gates LLP

300 South Tryon Street, 10th Floor

Charlotte, North Carolina 28202

Attention: Sean M. Jones

Email:  sean.jones@klgates.com

 

Any party to this Agreement
may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.

 

Section 6.6    Severability.
In the event that any provision of this Agreement shall be declared invalid or unenforceable by any regulatory body or court having
jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remaining portions of
this Agreement.

 

Section 6.7    No
Third-Party Beneficiary. Nothing in this Agreement is intended or shall be construed to give any person, other than the
parties, their successors and permitted assigns, any legal or equitable right, remedy or claim under or in respect of this Agreement
or any provision contained herein.

 

    18

     

    

 

Section 6.8    Suits.
Any legal suit, action or proceeding arising out of, or based upon, this Agreement or the transactions contemplated hereby, may
be instituted in any state or federal court located in the Borough of Manhattan, New York, New York (each, a “New York
Court”), and each party hereby waives, to the fullest extent it may effectively do so, any objection which it may now
or hereafter have, to the laying of venue of any such proceeding and submits to the exclusive jurisdiction of such courts in any
such legal suit, action or proceeding. Each party hereby waives irrevocably any immunity to jurisdiction to which it may otherwise
be entitled or become entitled (including sovereign immunity, immunity to pre-judgment attachment, post-judgment attachment and
execution), in any legal suit, action or proceeding against it arising out of, or based upon, this Agreement or the transactions
contemplated hereby, that is instituted in any New York Court. Process in any such legal suit, action or proceeding may be served
on any party anywhere in the world, whether within or without the jurisdiction of any such court.

 

Section 6.9    WAIVER
OF JURY TRIAL. Each party hereby irrevocably waives, to the fullest extent permitted
by applicable law, any and all right to trial by jury in any legal proceeding arising out of or based upon this Agreement, THE
SECURITIES or the transactions contemplated hereby.

 

Section 6.10    Survival.
All representations, warranties and covenants contained herein shall survive the execution and delivery of this Agreement and the
New Notes.

 

[Signature Page Follows.]

 

    19

     

    

 

IN WITNESS WHEREOF, each of the parties
hereto has caused this Agreement to be executed as of the date first above written.

 

COMPANY 

 

	Teligent, Inc.
	 
	By:	          	 
	Name:	         
	Title:	         

 

[Signature page
to Note Exchange Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, each of the parties
hereto has caused this Agreement to be executed as of the date first above written.

 

	 	“UNDERSIGNED ENTITY”:
	 	(in its capacities described
    in the first paragraph hereof)
	 	 
	 	[_________________]
	 	 
	 	By:	            
	 	Name:	
	 	Title:	            

 

[Signature page
to Note Exchange Agreement]

 

     

     

    

 

Exhibit A

 

	Holder	Aggregate Principal

 Amount - Old Notes 	Aggregate Principal

 Amount – New Notes	DTC Number	Broker Name and Contact

 Information (individual’s

 name, phone and email)
	[____________]	[   •   ]	[   •   ]	[   •   ]	
        [____________]

	Total	[   •   ]	[   •   ]Exhibit 10.19

 

CONTRACT

 

THIS
AGREEMENT effective this 1st of September 2020, by and between SunHydrogen, Inc (hereafter referred to as "Sponsor")
and The University of Iowa, Iowa City, Iowa, a non-profit educational institution (hereinafter referred to as "University").

 

WITNESSETH:

 

WHEREAS,
the research program contemplated by this Agreement is of mutual interest and benefit to University and to Sponsor, will further
the instructional and research objectives of University in a manner consistent with its status as a non- profit, tax-exempt, educational
institution, and may derive benefits for both Sponsor and University through inventions, improvements, and/or discoveries;

 

NOW,
THEREFORE, in consideration of the premises and mutual covenants herein contained, the parties hereto agree to the following:

 

ARTICLE
1 - Definitions

 

As
used herein, the following terms shall have the following meanings:

 

		1.1	"Project"
                                         shall mean the description of the project as described in Exhibit A hereof, under the
                                         direction of Syed Mubeen as Principal Investigator.

 

		1.2	"Contract
                                         Period" is Sep 1, 2020, through Aug 31, 2021.

 

		1.3	"University
                                         Intellectual Property" shall mean individually and collectively all inventions,
                                         improvements and/or discoveries which are conceived and/or made (i) by one or more employees
                                         of University, or (ii) jointly by one or more employees of University and by one or more
                                         employees/consultants of Sponsor, in performance of the Project.

 

ARTICLE
2 - Research Work

 

		2.1	University
                                         shall commence performance of the Project promptly after the effective date of this Agreement,
                                         and shall use all reasonable efforts, care, and diligence to perform such Project in
                                         accordance with the terms and conditions of this Agreement. Anything in this Agreement
                                         to the contrary notwithstanding, Sponsor and University may at any time amend the Project
                                         by mutual written agreement.

 

		2.2	In
                                         the event that the Principal Investigator becomes unable or unwilling to continue the
                                         Project, and a mutually acceptable substitute is not available, University and/or Sponsor
                                         shall have the option to terminate said Project pursuant to Article 10.1.

 

		2.3	The
                                         University does not comply with Good Laboratory Practices (GLPs) as defined by the U.S.
                                         Food and Drug Administration in 21 C.F.R. 58.

 

    -1-

     

    

 

ARTICLE
3 - Reports and Conferences

 

		3.1	Written
                                         program reports shall be provided by University to Sponsor every six (6) months, and
                                         a final report shall be submitted by University within forty-five (45) days of the conclusion
                                         of the Contract Period, or the earlier termination of this Agreement.

 

		3.2	During
                                         the term of this Agreement, representatives of University will meet with representatives
                                         of Sponsor at times and places mutually agreed upon to discuss the progress and results,
                                         as well as ongoing plans, or changes therein, of the Project to be performed hereunder.

 

ARTICLE
4 - Costs, Billings, and Other Support

 

		4.1	It
                                         is agreed to and understood by the parties hereto that, subject to Article 2, total costs
                                         to Sponsor hereunder shall not exceed the sum of Two Hundred and Ninety-Nine Thousand
                                         and Nine Hundred and Sixty-Six Dollars ($299, 966). Payment shall be made by Sponsor
                                         according to the following schedule:

 

Four
(4) Quarterly Payments of $74,991.5

 

		4.2	Invoices
                                         shall be submitted to the Sponsor representative listed in Article 17 for submission
                                         of invoices. Payments to University shall include Sponsor name, Principal Investigator
                                         name, project title and shall be submitted to the University representative listed in
                                         Article 17 for payment remittance.

 

		4.3	[Sponsor
                                         shall loan/donate the following equipment to University under the following conditions:      Not
                                         Applicable                           .] University shall retain title to any equipment purchased with
                                         funds provided by Sponsor under this Agreement.

 

		4.4	Anything
                                         herein to the contrary notwithstanding, in the event of early termination of this Agreement
                                         by Sponsor pursuant to Article 10.1 hereof, Sponsor shall pay all costs accrued by University
                                         as of the date of termination, including non-cancelable obligations, which shall include
                                         all non-cancelable contracts and fellowships or postdoctoral associate appointments called
                                         for in Appendix A, incurred prior to the effective date of termination. After termination,
                                         any obligation of Sponsor for fellowships or postdoctoral associates shall end no later
                                         than the end of University's academic year following termination.

 

ARTICLE
5 - Publicity

 

		5.1	Sponsor
                                         shall not use the name of University, nor of any member of University's Project staff,
                                         in any publicity, advertising, or news release or in any way imply endorsement of the
                                         University without the prior written approval of an authorized representative of University.
                                         University shall not use the name of Sponsor, nor any employee of Sponsor, in any publicity
                                         without the prior written approval of Sponsor. University may disclose, without Sponsor’s
                                         approval, the terms of this Agreement that are a matter of public record under the Iowa
                                         Open Records Law, Iowa Code Chapter 22.

 

    -2-

     

    

 

ARTICLE
6 - Publications

 

		6.1	Sponsor
                                         recognizes that under University policy, the results of University research must be publishable
                                         and agrees that researchers engaged in the Project shall be permitted to present research
                                         results at symposia, national or regional professional meetings, and to publish in journals,
                                         theses or dissertations, or otherwise of their own choosing, methods and results of the
                                         Project, provided, however, that Sponsor shall have been furnished copies of any proposed
                                         publication or presentation at least one (1) month in advance of the submission of such
                                         proposed publication or presentation to a journal, editor, or other third party. Sponsor
                                         shall have thirty (30) days, after receipt of said copies, to object to such proposed
                                         presentation or proposed publication because there is patentable subject matter or proprietary
                                         information of Sponsor that needs protection. In the event that Sponsor makes such objection,
                                         said researcher(s) shall refrain from making such publication or presentation for a maximum
                                         of six (6) months from date of receipt of such objection in order for University to file
                                         patent application(s) with the United States Patent and Trademark Office and/or foreign
                                         patent office(s) directed to the patentable subject matter contained in the proposed
                                         publication or presentation. Sponsor does not possess a right to delay publication if
                                         the publication or presentation contains only findings and conclusions of basic science
                                         or results that would not affect the ability of Sponsor to obtain a patent.

 

ARTICLE
7 - Proprietary Information

 

		7.1	It
                                         is the responsibility of Sponsor to mark or otherwise identify in writing prior to submission
                                         any information considered confidential that it deems necessary to share with University
                                         (“Confidential Information”). Oral disclosures of Confidential Information
                                         shall be identified as confidential at the time of disclosure and confirmed in writing
                                         within ten (10) business days of the disclosure. University shall have the right to accept
                                         or reject Sponsor’s Confidential Information. If such information is accepted it
                                         will be withheld by University from publication, and in all other respects shall be maintained
                                         by University as confidential and proprietary to Sponsor for a period of five (5)
years after termination of this Agreement. University shall have no such obligation with respect to any portion of such Confidential
Information which:

 

		a)	is
                                         or later becomes generally available to the public by use, publication or the like, through
                                         no fault of University;

 

		b)	is
                                         obtained on a non-confidential basis from a third party who disclosed the same to University;

 

		c)	University
                                         already possesses, as evidenced by its written records, predating receipt thereof from
                                         Sponsor; or

 

		d)	is
                                         required to be disclosed by law, regulation or court order.

 

		7.2	All
                                         documentation concerning University Intellectual Property submitted to Sponsor in accordance
                                         with Article 8.4 shall be treated as confidential in order to preserve any patent rights.

 

    -3-

     

    

 

ARTICLE
8 - Intellectual Property

 

		8.1	All
                                         rights, title and interest to University Intellectual Property under the Project, except
                                         as provided in Article 8.3, shall belong to University and shall be subject to the terms
                                         and conditions of this Agreement.

 

		8.2	Rights
                                         to inventions, improvements, and/or discoveries, whether patentable or copyrightable
                                         or not, relating to the Project made solely by employees /consultants
of Sponsor shall belong to Sponsor. Such inventions, improvements, and/or discoveries shall not be subject to the terms and conditions
of this Agreement.

 

		8.3	Rights
                                         to inventions, improvements, and/or discoveries conceived and/or made during the Contract
                                         Period, whether patentable or copyrightable or not, relating to the Project, which are
                                         made jointly by employees of University and employees/consultants of Sponsor, shall be
                                         the joint property of University and Sponsor and shall be subject to the terms and conditions
                                         of this Agreement.

 

		8.4	University
                                         will promptly notify Sponsor of any University Intellectual Property conceived and/or
                                         made during the Contract Period under the Project. If Sponsor directs that a patent application
                                         or application for other intellectual property protection be filed, University shall
                                         promptly prepare, file, and prosecute such U.S. and foreign application in University's
                                         name, and Sponsor’s name if jointly invented. Sponsor shall bear all costs incurred
                                         in connection with such preparation, filing, prosecution, and maintenance of U.S.
and foreign application(s) directed to said University Intellectual Property. Sponsor shall cooperate with University to assure
that such application(s) will cover, to the best of Sponsor's knowledge, all items of commercial interest and importance. While
University shall be responsible for making decisions regarding scope and content of application(s) to be filed and prosecution
thereof, Sponsor shall be given an opportunity to review and provide input thereto. University shall keep Sponsor advised as to
all developments with respect to such application(s) and shall promptly supply to Sponsor copies of all papers received and filed
in connection with the prosecution thereof in sufficient time for Sponsor to comment thereon.

 

		8.5	If
                                         Sponsor elects not to exercise its option granted in Article 9.1 or decides to discontinue
                                         the financial support of the prosecution and maintenance of the patent protection, all
                                         right, title and interest in such patent, patent application, and University Intellectual
                                         Property shall automatically revert to University. University shall then be free to file
                                         or continue prosecution or maintain any such application(s), and to maintain any protection
                                         issuing thereon in the U.S. and in any foreign country at University's sole expense.

 

ARTICLE
9 - Grant of Rights

 

		9.1	Subject
                                         to Article 8.3, University grants Sponsor the first option to elect an exclusive license
                                         to University Intellectual Property developed under this Agreement, and a right to sub-license
                                         any and all University Intellectual Property developed under this Agreement on terms
                                         and conditions to be mutually agreed upon. If Sponsor elects to exercise this option,
                                         Sponsor shall notify
University in writing of its decision within one (1) year from the date of termination of this Agreement.

 

    -4-

     

    

 

		9.2	No
                                         grant described in this Article shall be construed to limit University’s right
                                         to utilize University Intellectual Property for research, instruction or academic publication
                                         purposes.

 

ARTICLE
10 - Term and Termination

 

		10.1	This
                                         Agreement shall become effective upon the date first hereinabove written and shall continue
                                         in effect for the full duration of the Contract Period unless sooner terminated in accordance
                                         with the provisions of this Article. The parties hereto may, however, extend the term
                                         of this Agreement for additional periods as desired under mutually agreeable terms and
                                         conditions which the parties reduce to writing and sign. Either party may terminate this
                                         Agreement upon sixty (60) days prior written notice to the other.

 

		10.2	In
                                         the event that either party hereto shall commit any material breach or default in any
                                         of the terms or conditions of this Agreement, and also shall fail to remedy such default
                                         or breach within ninety (90) days after receipt of written notice thereof from the other
                                         party hereto, the party giving notice may, at its option and in addition to any other
                                         remedies which it may have at law or in equity, terminate this Agreement by sending notice
                                         of termination in writing to the other party to such effect, and such termination shall
                                         be effective as of the date of the receipt of such notice.

 

		10.3	Termination
                                         of this Agreement by either party for any reason shall not affect the rights and obligations
                                         of the parties accrued prior to the effective date of termination of this Agreement.
                                         No termination of this Agreement, however effectuated, shall release the parties hereto
                                         from their rights and obligations under Articles 3.1, 4, 5, 6, 7, 8, 9 and 11.

 

ARTICLE
11 - Independent Contractor

 

	 	11.1	In
                                         the performance of all services hereunder University shall be deemed to be and shall
                                         be an independent contractor and, as such, University shall not be entitled to any benefits
                                         applicable to employees of Sponsor.
	 	 	 
		11.2	Neither
                                         party is authorized or empowered to act as agent for the other for any purpose and shall
                                         not on behalf of the other enter into any contract, warranty, or representation as to
                                         any matter. Neither shall be bound to the acts or conduct of the other.

 

ARTICLE
12 – Insurance

 

		12.1	Each
                                         party shall be liable for any and all claims for wrongful death, personal injury or property
                                         damage attributable to the negligent acts or omissions of that party and the officers,
                                         employees, and agents thereof.

 

    -5-

     

    

 

		12.2	University
                                         shall be responsible and agrees to pay for any and all claims for wrongful death, personal
                                         injury or property damage directly resulting from the negligence of University, its officers,
                                         employees and agents, and arising from activities under this Agreement to the full extent
                                         permitted by Chapter 669, Code of Iowa, which is the exclusive remedy for processing
                                         tort claims against the State of Iowa.

 

ARTICLE
13 - Governing Law

 

		13.1	This
                                         Agreement shall be governed and construed in accordance with the substantive laws of
                                         the State of Iowa, excluding its conflict of laws provisions.

 

ARTICLE
14 - Assignment

 

		14.1	This
                                         Agreement shall not be assigned by either party without the prior written consent of
                                         the parties hereto.

 

		14.2	This
                                         Agreement is assignable to any division of Sponsor, any majority stockholder of Sponsor,
                                         and/or any subsidiary of Sponsor, provided that such assignee assumes all of the rights,
                                         obligations and liabilities of Sponsor hereunder.

 

ARTICLE
15 - Agreement Modification

 

		15.1	Any
                                         agreement to change the terms of this Agreement in any way shall be valid only if the
                                         change is made in writing and approved by mutual agreement of authorized representatives
                                         of the parties hereto.

 

ARTICLE
16 - Warranties

 

		16.1	NO
                                         WARRANTIES, EITHER EXPRESSED OR IMPLIED, ARE MADE PART OF THIS AGREEMENT.

 

ARTICLE
17 – Export Control

 

		17.1	The
                                         disclosing party agrees to share any export control determinations when products, services,
                                         and/or technical data under this Agreement are subject to export controls under U.S.
                                         Government export laws and regulations; however, each party will be solely responsible
                                         for compliance with U.S. Government export laws and regulations.

 

ARTICLE
18 - Notices

 

		18.1	Notices,
                                         invoices, and communications, hereunder shall be given by registered or certified mail,
                                         or express delivery service, postage or delivery charge prepaid, and addressed to the
                                         party to receive such notice, invoice, or communication at the address given below, or
                                         such other address as may hereafter be designated by notice in writing. Notice shall
                                         be deemed made on the date of receipt.

 

    -6-

     

    

 

If
to Sponsor:

 

Tim
Young, CEO

SunHydrogen, Inc

Phone:
(310)486-0740

E-mail:tyoung@sunhydrogen.com

 

For
Submission of Invoices:

SunHydrogen,
Inc.

32
E. Micheltorena, Suite A Santa

Barbara, CA 93101

Phone:
805-966-6566

Fax:
805-617-3601

E-mail:
tyoung@sunhydrogen.com

 

If
to University:                The University of Iowa

Division
of Sponsored Programs

Attention:
                   

 2 Gilmore Hall

Iowa
City, Iowa 52242

Phone: 319-335-2123

Fax:
319-335-2130

E-mail:

 

For
Payment Remittance:

 

The
University of Iowa 

Grant Accounting Office 

B5 Jessup Hall

Iowa
City, Iowa 52242-1316 Phone: 319-335-3801

Fax:
319-335-0674

 

IN
WITNESS WHEREOF, the parties, duly authorized, have executed this Agreement in duplicate as of the day and year first written
above.

 

	SUNHYDROGEN,
    INC. (SPONSOR)	 	THE
    UNIVERSITY OF IOWA
	 	 	 	 	 
	By:	/s/
    Timothy Young	 	By:	/s/
    Jennifer Lassner
	Name: 	Timothy
    Young	 	Name: 	Jennifer
    Lassner
	Title: 	President
    and CEO	 	Title: 	Executive
    Director of Sponsored Programs
	 	 	 	 	 
	Date:	
	 	Date:	

 

Rev.
03/30/2012

 

 

-7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]